Prelude Therapeutics’ lead asset won’t be making it to the second act. The precision oncology outfit is pausing development of SMARCA2 degrader PRT3789, leaving just one clinical program left humming ...

Immuneering has reported 94% overall survival (OS) at six months in first-line pancreatic cancer, emboldening the biotech to start planning a pivotal trial to support accelerated approval of its MEK ...

Merck shares rose after partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment ...

Biotech investors are once again rotating aggressively into clinical-stage growth stories as a fresh wave of capital ...

Biotech stocks tied to cancer, autoimmune and rare disease therapies gain attention as M&A activity boosts sector sentiment.

Phio Pharmaceuticals Corp. PHIO shares are up on Tuesday’ as the company announced positive results from its Phase 1b clinical trial for its lead candidate, PH-762. The $9 million market cap biotech ...

IO Biotech's co-founder presented advancements in cancer vaccines at the 2025 AACR Annual Meeting, highlighting innovative therapeutic strategies. IO Biotech, a clinical-stage biopharmaceutical ...

By Siddhi Mahatole May 21 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment ...

ACCRA, Ghana & WASHINGTON--(BUSINESS WIRE)--Yemaachi Biotech, a pioneering genomics research company based in Ghana, announced today a partnership with Roche to launch The African Cancer Atlas (TACA).

Andrew Wilks, who won the Prime Minister’s Prize for Innovation in 2024, has warned Labor’s tax changes will drive away ...